NRG-LU006

Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy with or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM)

Principal Investigator

Andreas Rimner, MD

Status

Disease Site

Lung [LU] Mesothelioma

Phase

III

Developmental Therapeutics

No

Primary Objective

To detect an improvement in overall
survival with the addition of adjuvant hemithoracic IMPRINT to surgery and
chemotherapy compared to surgery and chemotherapy alone.

Patient Population

Patients with pathologically (histologically or cytologically) confirmed diagnosis of epithelioid or biphasic MPM, amenable to MCR, within 90 days prior to Step 1 Registration

Target Accrual

150